search
Back to results

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (CHIPPI)

Primary Purpose

Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
HIPEC
Sponsored by
Centre Oscar Lambret
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ovary Neoplasms focused on measuring Ovarian cancer, Hyperthermic intraperitoneal chemotherapy, HIPEC, Primary Debulking Surgery, Interval Debulking Surgery

Eligibility Criteria

18 Years - 76 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

Pre-eligibility criteria to be checked before surgery for pre-registration

  1. Age ≥18 years and ≤ 76 years
  2. Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell carcinoma, mucinous adenocarcinoma and endometrioid carcinoma)
  3. Pre-therapeutic FIGO (International Federation of Gynecology and Obstetrics) stage III
  4. Patient eligible for

    1. Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy
    2. Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/- bevacizumab or other targeted therapy, with or without planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks if chemotherapy is combined with bevacizumab. The patient remains eligible for the study if surgery is delayed beyond the recommended time interval.
  5. WHO (World Health Organization Performance Status) ≤ 2
  6. Physical status score ASA (American Society of Anesthesiologists) ≤ 2
  7. Adequate bone marrow and renal function, as evidenced by the following tests performed within 7 days prior to surgery:

    • Absolute Neutrophil Count (ANC) ≥1,500/mm3
    • Platelets ≥100,000/mm3
    • Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) (≤5.0 × ULN in case of liver metastases)
    • Total bilirubin ≤1.5 × ULN (except in case of Gilbert's disease)
    • Creatinine clearance ≥ 60 mL/ min
  8. Negative serum pregnancy test within 7 days prior to surgery for women of childbearing potential. For non-menopausal women, if no hysterectomy is planned, willing to accept the use of an effective contraceptive regimen during the treatment period and at least 6 months after the end of treatment (surgery or adjuvant chemotherapy)
  9. Absence of contraindication to receive the products used in this study (cisplatin and products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent SmPC (Summary of Product Characteristics) of these products
  10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up
  11. Signed written informed consent
  12. Patient covered by the French or Belgian "Social Security" regime Criteria to be checked per-operatively for confirmation of enrolment and randomization
  13. Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue) or CC-1 (residue < 2.5 mm)
  14. Per-operative hemorrhage < 2.5 L
  15. Strictly less than 3 digestive resections performed during surgery
  16. Diuresis maintained during surgery, without oliguria or anuria (per-operatory diuresis ≥ 0,5 mL/ kg/ h)

Exclusion Criteria:

  1. Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma
  2. Cirrhosis
  3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
  4. Auditory impairment
  5. Dehydration or intercurrent disease that contraindicates hyperhydration (including cardio-respiratory disease)
  6. Other uncontrolled intercurrent disease including, but not limited to: diabetes; hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or severe gastrointestinal (associated with diarrhea) chronic disease
  7. Any unresolved NCI-CTCAE Grade ≥ 2 toxicity from previous anticancer therapy (excluding alopecia)
  8. Concomitant treatment with prophylactic phenytoin
  9. Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days prior to inclusion (and, if patient is enrolled, up to 30 days after the last administration of study treatment)
  10. Pregnant or breastfeeding woman
  11. Psychiatric illness or social situation that would limit compliance with study requirement, substantially increase the risk of side effects, or compromise the ability of the patient to give written informed consent
  12. Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
  13. Person under guardianship

Sites / Locations

  • Cliniques universitaires St-Luc, Institut Roi Albert IIRecruiting
  • Institut de Cancérologie de l'OuestRecruiting
  • Institut Bergonié
  • Centre François BaclesseRecruiting
  • Centre Jean PerrinRecruiting
  • Centre Oscar LambretRecruiting
  • Hôpital Jeanne de FlandreRecruiting
  • Institut Paoli CalmettesRecruiting
  • ICM-Val d'AurelleRecruiting
  • Hôpital Européen Georges PompidouRecruiting
  • Centre Hospitalier Lyon SudRecruiting
  • Clinique MathildeRecruiting
  • Centre Henri BecquerelRecruiting
  • Institut de Cancérologie de l'Ouest
  • Hôpital de Hautepierre
  • Institut de Cancérologie de LorraineRecruiting
  • Institut Gustave Roussy

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Arm A (PDS or IDS + HIPEC)

Arm B (PDS or IDS)

Arm Description

Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy) Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery). Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.

Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC) Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery). Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.

Outcomes

Primary Outcome Measures

Disease-free Survival (DFS)
The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone.

Secondary Outcome Measures

Overall survival
The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care.
Adverse events (AE)
The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery.
Q-TWiST
Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data.
Quality of life of the patient (QLQC30)
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients.
Quality of life of the patient (QLQOV28)
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients.

Full Information

First Posted
February 13, 2019
Last Updated
December 6, 2022
Sponsor
Centre Oscar Lambret
search

1. Study Identification

Unique Protocol Identification Number
NCT03842982
Brief Title
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
Acronym
CHIPPI
Official Title
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2019 (Actual)
Primary Completion Date
August 1, 2027 (Anticipated)
Study Completion Date
August 1, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Oscar Lambret

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.
Detailed Description
The primary objective of this study is to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC treatment combined with standard care (PDS or IDS) or standard care alone (PDS or IDS alone). Secondary objectives of the study include: Evaluating the efficacy of HIPEC in terms of overall survival (OS) in combination with standard of care Evaluating the morbidity associated with HIPEC. Evaluating the trade-off between efficacy and morbidity using the Q-TWiST approach. Evaluating the impact of HIPEC in terms of quality of life. Exploratory objectives (optional) include: Evaluating the impact of HIPEC on the count of residual viable cells (evaluated by flow cytometry) in abdominal drainage fluids for patients recruited in Centre Oscar Lambret only. Constituting a biobank (tumoral samples and blood samples) for future translational researches

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma
Keywords
Ovarian cancer, Hyperthermic intraperitoneal chemotherapy, HIPEC, Primary Debulking Surgery, Interval Debulking Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
362 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A (PDS or IDS + HIPEC)
Arm Type
Experimental
Arm Description
Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy) Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery). Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.
Arm Title
Arm B (PDS or IDS)
Arm Type
No Intervention
Arm Description
Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC) Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery). Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.
Intervention Type
Drug
Intervention Name(s)
HIPEC
Other Intervention Name(s)
Hyperthermic intraperitoneal chemotherapy
Intervention Description
HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate. Administration of the dose should be according the following schedule: 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion. The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.
Primary Outcome Measure Information:
Title
Disease-free Survival (DFS)
Description
The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone.
Time Frame
From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)
Secondary Outcome Measure Information:
Title
Overall survival
Description
The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care.
Time Frame
From randomization to first progression, relapse or death from any cause , whichever came first, assessed up to 5 years..
Title
Adverse events (AE)
Description
The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery.
Time Frame
Covers the whole treatment duration from Randomization up to the end of treatment (surgery or CT) plus 30 days.
Title
Q-TWiST
Description
Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data.
Time Frame
Over the 5 year surveillance period
Title
Quality of life of the patient (QLQC30)
Description
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients.
Time Frame
Up to 2 years after the end of treatment (every 3 month)
Title
Quality of life of the patient (QLQOV28)
Description
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients.
Time Frame
Up to 2 years after the end of treatment (every 3 month)

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Women with ovarian cancer
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
76 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pre-eligibility criteria to be checked before surgery for pre-registration Age ≥18 years and ≤ 76 years Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell carcinoma, mucinous adenocarcinoma and endometrioid carcinoma) Pre-therapeutic FIGO (International Federation of Gynecology and Obstetrics) stage III Patient eligible for Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/- bevacizumab or other targeted therapy, with or without planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks if chemotherapy is combined with bevacizumab. The patient remains eligible for the study if surgery is delayed beyond the recommended time interval. WHO (World Health Organization Performance Status) ≤ 2 Physical status score ASA (American Society of Anesthesiologists) ≤ 2 Adequate bone marrow and renal function, as evidenced by the following tests performed within 7 days prior to surgery: Absolute Neutrophil Count (ANC) ≥1,500/mm3 Platelets ≥100,000/mm3 Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) (≤5.0 × ULN in case of liver metastases) Total bilirubin ≤1.5 × ULN (except in case of Gilbert's disease) Creatinine clearance ≥ 60 mL/ min Negative serum pregnancy test within 7 days prior to surgery for women of childbearing potential. For non-menopausal women, if no hysterectomy is planned, willing to accept the use of an effective contraceptive regimen during the treatment period and at least 6 months after the end of treatment (surgery or adjuvant chemotherapy) Absence of contraindication to receive the products used in this study (cisplatin and products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent SmPC (Summary of Product Characteristics) of these products Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up Signed written informed consent Patient covered by the French or Belgian "Social Security" regime Criteria to be checked per-operatively for confirmation of enrolment and randomization Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue) or CC-1 (residue < 2.5 mm) Per-operative hemorrhage < 2.5 L Strictly less than 3 digestive resections performed during surgery Diuresis maintained during surgery, without oliguria or anuria (per-operatory diuresis ≥ 0,5 mL/ kg/ h) Exclusion Criteria: Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma Cirrhosis Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation Auditory impairment Dehydration or intercurrent disease that contraindicates hyperhydration (including cardio-respiratory disease) Other uncontrolled intercurrent disease including, but not limited to: diabetes; hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or severe gastrointestinal (associated with diarrhea) chronic disease Any unresolved NCI-CTCAE Grade ≥ 2 toxicity from previous anticancer therapy (excluding alopecia) Concomitant treatment with prophylactic phenytoin Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days prior to inclusion (and, if patient is enrolled, up to 30 days after the last administration of study treatment) Pregnant or breastfeeding woman Psychiatric illness or social situation that would limit compliance with study requirement, substantially increase the risk of side effects, or compromise the ability of the patient to give written informed consent Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons) Person under guardianship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie VANSEYMORTIER
Phone
+33 3 20 29 59 18
Email
promotion@o-lambret.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Fabrice MULOT
Phone
+33 3 20 29 59 18
Email
promotion@o-lambret.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabrice NARDUCCI, MD
Organizational Affiliation
Centre Oscar Lambret, Lille, France
Official's Role
Study Director
Facility Information:
Facility Name
Cliniques universitaires St-Luc, Institut Roi Albert II
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florence FONTAINE
Phone
+32 02 764 85 09
Email
florence.fontaine@uclouvain.be
First Name & Middle Initial & Last Name & Degree
Karoline AMANN
Email
karoline.amann@uclouvain.be
Facility Name
Institut de Cancérologie de l'Ouest
City
Angers
ZIP/Postal Code
49055
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Romuald WERNERT, MD
Email
romuald.wernert@ico.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Romuald WERNERT, MD
First Name & Middle Initial & Last Name & Degree
Pedro RARO, MD
First Name & Middle Initial & Last Name & Degree
Valeria DE FRANCO, MD
First Name & Middle Initial & Last Name & Degree
Augustin REYNARD, MD
First Name & Middle Initial & Last Name & Degree
Patrick SOULIE, MD
First Name & Middle Initial & Last Name & Degree
Sophie ABADIE-LACOURTOISIE, MD
First Name & Middle Initial & Last Name & Degree
Paule AUGEREAU, MD
First Name & Middle Initial & Last Name & Degree
Anne PATSOURIS, MD
First Name & Middle Initial & Last Name & Degree
Elouen BOUGHALEM, MD
First Name & Middle Initial & Last Name & Degree
Frédéric BIGOT, MD
First Name & Middle Initial & Last Name & Degree
Margot NOBLECOURT, MD
First Name & Middle Initial & Last Name & Degree
Victor SIMMET, MD
First Name & Middle Initial & Last Name & Degree
Marion DE VRIES, MD
Facility Name
Institut Bergonié
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Coriolan LEBRETON
Email
c.lebreton@bordeaux.unicancer.fr
Email
f.guyon@bordeaux.unicancer.fr
Facility Name
Centre François Baclesse
City
Caen
ZIP/Postal Code
14076
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandrine MARTIN-FRANCOISE, MD
Email
marsa@baclessse.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Sandrine MARTIN-FRANCOISE, MD
First Name & Middle Initial & Last Name & Degree
Jean François LE BRUN, MD
First Name & Middle Initial & Last Name & Degree
Florence JOLY, MD
First Name & Middle Initial & Last Name & Degree
Emeline MERIAUX, MD
Facility Name
Centre Jean Perrin
City
Clermont-Ferrand
ZIP/Postal Code
63011
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe POMEL, MD
Email
christophe.pomel@clermont.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Christophe POMEL, MD
First Name & Middle Initial & Last Name & Degree
Caroline CORNOU, MD
First Name & Middle Initial & Last Name & Degree
Sophie DUBOIS, MD
First Name & Middle Initial & Last Name & Degree
Morgane MASSON, MD
First Name & Middle Initial & Last Name & Degree
Marie-Ange MOURET-REYNIER, MD
Facility Name
Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabrice NARDUCCI, MD
Email
f-narducci@o-lambret.fr
First Name & Middle Initial & Last Name & Degree
Fabrice NARDUCCI, MD
First Name & Middle Initial & Last Name & Degree
Delphine HUDRY, MD
First Name & Middle Initial & Last Name & Degree
Eric LEBLANC, MD
First Name & Middle Initial & Last Name & Degree
Cyril ABDEDDAIM, MD
First Name & Middle Initial & Last Name & Degree
Annick CHEVALIER-PLACE, MD
First Name & Middle Initial & Last Name & Degree
Alfred BASSIL, MD
First Name & Middle Initial & Last Name & Degree
Charlotte BELLIER, MD
First Name & Middle Initial & Last Name & Degree
Valérie CHEVALIER-EVAIN, MD
First Name & Middle Initial & Last Name & Degree
Emilie KACZMAREK, MD
First Name & Middle Initial & Last Name & Degree
Samira MAKHLOUFI, MD
Facility Name
Hôpital Jeanne de Flandre
City
Lille
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre COLLINET, MD, PhD
Email
pierre.collinet@chru-lille.fr
First Name & Middle Initial & Last Name & Degree
Pierre COLLINET, MD, PhD
First Name & Middle Initial & Last Name & Degree
Clarisse EVENO, MD
First Name & Middle Initial & Last Name & Degree
Jérôme PHALIPPOU, MD
First Name & Middle Initial & Last Name & Degree
Christophe DESAUW, MD
First Name & Middle Initial & Last Name & Degree
Anne PLOQUIN, MD
Facility Name
Institut Paoli Calmettes
City
Marseille
ZIP/Postal Code
13273
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric LAMBAUDIE, MD, PhD
Email
lambaudiee@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Eric LAMBAUDIE, MD, PhD
First Name & Middle Initial & Last Name & Degree
Gilles HOUVENAEGHEL, MD
First Name & Middle Initial & Last Name & Degree
Guillaume BLACHE, MD
First Name & Middle Initial & Last Name & Degree
Laura SABIANI, MD
First Name & Middle Initial & Last Name & Degree
Julien BARROU, MD
First Name & Middle Initial & Last Name & Degree
Maria Antonietta CAPPIELLO, MD
First Name & Middle Initial & Last Name & Degree
Magali PROVANSAL, MD
First Name & Middle Initial & Last Name & Degree
Frédérique ROUSSEAU, MD
First Name & Middle Initial & Last Name & Degree
Renaud SABATIER, MD
Facility Name
ICM-Val d'Aurelle
City
Montpellier
ZIP/Postal Code
34298
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre-Emmanuel COLOMBO, MD
Email
Pierre-Emmanuel.Colombo@icm.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Pierre-Emmanuel COLOMBO, MD
First Name & Middle Initial & Last Name & Degree
Sébastien CARRERE, MD
First Name & Middle Initial & Last Name & Degree
Anne MOURREGOT, MD
First Name & Middle Initial & Last Name & Degree
François QUENET, MD
First Name & Middle Initial & Last Name & Degree
Philippe ROUANET, MD
First Name & Middle Initial & Last Name & Degree
Olivia SGARBURA, MD
First Name & Middle Initial & Last Name & Degree
Véronique D'HONDT, MD
First Name & Middle Initial & Last Name & Degree
Michel FABBRO, MD
Facility Name
Hôpital Européen Georges Pompidou
City
Paris
ZIP/Postal Code
75008
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne-Sophie BATS, MD
Email
anne-sophie.bats@aphp.fr
First Name & Middle Initial & Last Name & Degree
Anne-Sophie BATS, MD
First Name & Middle Initial & Last Name & Degree
Nicolas DELANOY, MD
First Name & Middle Initial & Last Name & Degree
Henri AZAIS, MD
First Name & Middle Initial & Last Name & Degree
Enrica BENTIVEGNA, MD
First Name & Middle Initial & Last Name & Degree
Meriem KOUAL, MD
First Name & Middle Initial & Last Name & Degree
Huyên-Thu NGUYEN-XUAN, MD
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre-Bénite
ZIP/Postal Code
69495
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Naoual BAKRIN, MD
Email
naoual.bakrin@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Witold GERTYCH, MD
Email
witold.gertych@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Naoual BAKRIN, MD
First Name & Middle Initial & Last Name & Degree
Witold GERTYCH, MD
First Name & Middle Initial & Last Name & Degree
Olivier GLEHEN, MD
First Name & Middle Initial & Last Name & Degree
Vahan KEPENEKIAN, MD
First Name & Middle Initial & Last Name & Degree
Benoit YOU, MD
First Name & Middle Initial & Last Name & Degree
Pierre DESCARGUES, MD
First Name & Middle Initial & Last Name & Degree
Pierre-Adrien BOLZE, MD
Facility Name
Clinique Mathilde
City
Rouen
ZIP/Postal Code
76100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benoît RESCH, MD
Email
benoit.resch@clinique-mathilde.fr
First Name & Middle Initial & Last Name & Degree
Benoït RESCH, MD
First Name & Middle Initial & Last Name & Degree
Marc BARON, MD
First Name & Middle Initial & Last Name & Degree
Julien COGET, MD
First Name & Middle Initial & Last Name & Degree
Clotilde HENNETIER, MD
First Name & Middle Initial & Last Name & Degree
Morgane PERRIN, MD
First Name & Middle Initial & Last Name & Degree
Jean Jacques TUECH, MD
First Name & Middle Initial & Last Name & Degree
Alexandre MARQUE, MD
First Name & Middle Initial & Last Name & Degree
Sandrine MEZZANI, MD
First Name & Middle Initial & Last Name & Degree
Cécile HENNEBERT, MD
Facility Name
Centre Henri Becquerel
City
Rouen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agathe CROUZET, MD
Email
agathe.crouzet@chb.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Agathe CROUZET, MD
First Name & Middle Initial & Last Name & Degree
Julien CARRILHO, MD
First Name & Middle Initial & Last Name & Degree
Emmanuel DE GOURNAY, MD
First Name & Middle Initial & Last Name & Degree
Albane POTEAU, MD
First Name & Middle Initial & Last Name & Degree
Laetitia AUGUSTO, MD
First Name & Middle Initial & Last Name & Degree
Sophie GOUERANT, MD
First Name & Middle Initial & Last Name & Degree
Cécile GUILLEMET, MD
First Name & Middle Initial & Last Name & Degree
Marianne LEHEURTEUR, MD
First Name & Middle Initial & Last Name & Degree
Camille PETRAU, MD
Facility Name
Institut de Cancérologie de l'Ouest
City
Saint-Herblain
ZIP/Postal Code
44800
Country
France
Individual Site Status
Withdrawn
Facility Name
Hôpital de Hautepierre
City
Strasbourg
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chérif AKLADIOS, MD
Email
Cherif.AKlADlOS@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Thomas BOISRAME, MD
First Name & Middle Initial & Last Name & Degree
Chérif AKLADIOS, MD
First Name & Middle Initial & Last Name & Degree
Lauriane EBERST, MD
Facility Name
Institut de Cancérologie de Lorraine
City
Vandœuvre-lès-Nancy
ZIP/Postal Code
54519
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric MARCHAL, MD
Email
f.marchal@nancy.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Frédéric MARCHAL, MD
First Name & Middle Initial & Last Name & Degree
Yolanda FERNANDEZ DIEZ, MD
First Name & Middle Initial & Last Name & Degree
Céline GAVOILLE, MD
First Name & Middle Initial & Last Name & Degree
Marie-Christine KAMINSKY, MD
First Name & Middle Initial & Last Name & Degree
Cécilia CERIBELLI, MD
Facility Name
Institut Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Withdrawn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

We'll reach out to this number within 24 hrs